4Maertens JA.History of the development of azole derivatives.Clin Microbiol Infect 2004; 10:1-10.
5Espinel-Ingroff A.Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872)and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts.J Clin Microbiol 1998;36:2950-2956.
6Negroni R,Helou SH,Petri N,et al.Case study:posaconazole treatment of disseminated phaeohyphomycosis due to exophiala spinifera.Clin Infect Dis 2004;38:15-20.
7Wiederhold NP,Lewis RE.The echinocandin antifungals:an overview of the pharmacology,spectrum and clinical efficacy.Expert Opin Investig Drugs 2003;12:1313-1333.
8Nakai T,Uno J,Ikeda F,et al.In vitro antifungal activity of micafungin (FK463) against dimorphic fungi:comparison of yeast -like and mycelial forms.Antimicrob Agents Chemother 2003;47:1376-1381.
9Odabasi Z,Paetznick VL,Rodriguez JR,et al.In vitro activity of anidulafungin against selected clinically important mold isolates.Antimicrob Agents Chemother 2004;48:1912-1915.
10Romero-Martinez R,Wheeler M,Guerrero-Plata A,et al.Biosynthesis and functions of melanin in sporothrix schenckii.Infect Immun 2000; 68:3696-3703.
